| Autor: |
Lucijanic, Marko, Busic, Nikolina, Stojic, Josip, Barisic-Jaman, Mislav, Zagorec, Nikola, Lazibat, Karla, Pasaric, Antica, Vrkljan Vuk, Anamarija, Durlen, Ivan, Mitrovic, Josko, Luksic, Ivica, Barsic, Bruno |
| Zdroj: |
Expert Opinion on Drug Safety; December 2023, Vol. 22 Issue: 12 p1265-1270, 6p |
| Abstrakt: |
ABSTRACTBackgroundThere are uncertainties regarding associations of prior proton pump inhibitor (PPI) use with susceptibility for COVID-19 and risks associated with SARS-CoV-2 infection. We aimed to evaluate the associations of prior PPI use with outcomes in hospitalized patients with COVID-19.Research design and methodsWe have retrospectively evaluated a total of 5959 consecutively hospitalized patients with COVID-19 from a tertiary-level institution in the period 3/2020–6/2021. Associations of prior PPI use with outcomes of in-hospital mortality, mechanical ventilation, intensive care unit stay, venous thromboembolism, arterial thrombosis, major bleeding, bacteremia, and Clostridioides difficileinfection (C. diff.) were evaluated in entire and case-matched cohorts.ResultsAmong 5959 evaluated patients, there were 1967 (33%) PPI users. In an entire cohort, prior PPI use was associated with higher in-hospital mortality and higher occurrence of C. diff. Association of prior PPI use with mortality diminished, whereas association with C. diff. persisted after multivariable adjustments. In a matched cohort, prior PPI use was associated only with higher risk of C. diff. but not other outcomes in line with multivariable analysis.ConclusionsAlthough prior PPI use might not have a significant impact on clinical course and mortality of SARS-CoV-2 infection, it may predispose patients to the development of complications like higher occurrence of C. diff. and thus substantially impact the course of treatment. |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
